Stability of Fecal Specimens for Bacterial Diagnostics Investigated
By LabMedica International staff writers Posted on 23 Oct 2014 |

Image: Culture of Clostridium difficile from a stool sample after 24 hours of incubation on chromogenic medium forming typical black colonies (Photo courtesy of the Freeman Hospital).

Image: The C.DIFF QUIK CHEK kit for the diagnosis of Clostridium difficile (Photo courtesy of TECHLAB).
To test for Clostridium difficile in stool specimens transported from remote geographic locations is a challenge due to long transit times, often at room temperature.
Discrepancies in C. difficile detection rates using nucleic acid amplification tests (NAAT) and antigen, culture and cytopathic effect (CPE) tests have been reported which may be due differences in the load of organisms in the stool, sometimes very low in asymptomatic carriage, and determining the viable count for C. difficile may be needed to differentiate between asymptomatic colonization versus true disease.
Microbiologists at the St. Boniface Research Center (Winnipeg, MB, Canada) assessed the impact of storage at room temperature versus 4 °C for up to 72 hours on the stability of glutamate dehydrogenase antigen, Toxin A and B antigens, toxigenic culture and cytopathic effect testing. Twelve diagnostic stool samples that were tested on the day of collection and shown to be C. difficile toxin positive were used for this study. Sample aliquots of each stool were stored at room temperature and 4 °C and testing was repeated at 24, 48 and 72 hours.
Stools that were positive for the presence of glutamate dehydrogenase (GD) using the C.DIFF QUIK CHEK kit (TECHLAB; Blacksburg, VA, USA) and also positive for the presence of Toxin A/Toxin B when tested by TECHLAB’s TOX A/B QUIK CHEK kit were included in the study. Cytopathic effect (CPE) tests were conducted using Human Foreskin Fibroblast cells (Inter Medico; Markham, ON, Canada). The pellet from the sample used for the CPE test were processed and used to inoculate Clostridium difficile moxalactam norfloxacin (CDMN) agar (Oxoid Company; Nepean, ON, Canada). The glutamate dehyrdogenase antigen and toxigenic stool culture tests were shown to be 100% reproducible at room temperature and 4 °C for up to 72 hours. Toxin A and B antigen deteriorated to 70% by 72 hours at room temperature, but was 90% reproducible if held at 4 °C. The cytopathic effect assay was 90% reproducible by 72 hours at room temperature and 4 °C.
The authors concluded that if stool samples are held at room temperature, the Toxin A/B antigen testing is only stable for 48 hours and by 72 hours is only 70% sensitive. They recommended that for stool samples received from remote geographic locations where transport is at room temperature and may be up to 72 hours, a combination of GD antigen screening combined with NAAT is used to ensure optimal sensitivity. The study was published on June 30, 2014, in the Journal of Medical Microbiology & Diagnosis.
Related Links:
St. Boniface Research Center
TECHLAB
Inter Medico
Discrepancies in C. difficile detection rates using nucleic acid amplification tests (NAAT) and antigen, culture and cytopathic effect (CPE) tests have been reported which may be due differences in the load of organisms in the stool, sometimes very low in asymptomatic carriage, and determining the viable count for C. difficile may be needed to differentiate between asymptomatic colonization versus true disease.
Microbiologists at the St. Boniface Research Center (Winnipeg, MB, Canada) assessed the impact of storage at room temperature versus 4 °C for up to 72 hours on the stability of glutamate dehydrogenase antigen, Toxin A and B antigens, toxigenic culture and cytopathic effect testing. Twelve diagnostic stool samples that were tested on the day of collection and shown to be C. difficile toxin positive were used for this study. Sample aliquots of each stool were stored at room temperature and 4 °C and testing was repeated at 24, 48 and 72 hours.
Stools that were positive for the presence of glutamate dehydrogenase (GD) using the C.DIFF QUIK CHEK kit (TECHLAB; Blacksburg, VA, USA) and also positive for the presence of Toxin A/Toxin B when tested by TECHLAB’s TOX A/B QUIK CHEK kit were included in the study. Cytopathic effect (CPE) tests were conducted using Human Foreskin Fibroblast cells (Inter Medico; Markham, ON, Canada). The pellet from the sample used for the CPE test were processed and used to inoculate Clostridium difficile moxalactam norfloxacin (CDMN) agar (Oxoid Company; Nepean, ON, Canada). The glutamate dehyrdogenase antigen and toxigenic stool culture tests were shown to be 100% reproducible at room temperature and 4 °C for up to 72 hours. Toxin A and B antigen deteriorated to 70% by 72 hours at room temperature, but was 90% reproducible if held at 4 °C. The cytopathic effect assay was 90% reproducible by 72 hours at room temperature and 4 °C.
The authors concluded that if stool samples are held at room temperature, the Toxin A/B antigen testing is only stable for 48 hours and by 72 hours is only 70% sensitive. They recommended that for stool samples received from remote geographic locations where transport is at room temperature and may be up to 72 hours, a combination of GD antigen screening combined with NAAT is used to ensure optimal sensitivity. The study was published on June 30, 2014, in the Journal of Medical Microbiology & Diagnosis.
Related Links:
St. Boniface Research Center
TECHLAB
Inter Medico
Latest Microbiology News
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
- Culture-Free Platform Rapidly Identifies Blood Stream Infections
- POC PCR Test Rapidly Detects Bacterial Meningitis Directly at Point of Sample Collection
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read morePathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more